Home
overview

SMi’s 15th Annual Conference
Parallel Trade 
March 22-23, 2021 | London, United Kingdom
-------------------------------------------------------------------------
SMi presents its 15th annual Parallel Trade virtual conference, taking place in London on the 22nd and the 23rd March 2021. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The 2021 event will be more significant than ever before due to the transition period after Brexit coming to an end this year. As such, the UK will no longer be part of the EU free market. This will mean increased medicines prices, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment, exhaustion of rights will cease to apply to the UK, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution.

This conference will bring together industry experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the FMD (Falsified Medicines Directive). The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states.


 

Learn new perspectives and case studies through presentation, panel discussions and interactive workshops from industry KOLs. Engage in a platform discussion inclusive of all different facets of parallel trade in analysing the overall state of the market. Explore the effects and impact of the Falsified Medicines Directive and how to best comply to these practices. Collaborate and share ideas of how a hard Brexit will impact the EU market and affect parallel trade practices. Discover what the industry has learnt from COVID-19 and the impact on export bans
 

The SMi Virtual Conference Platform will deliver the following benefits:

• Live and On Demand speaker content: Get access to the latest strategies and case studies from your marketplace online!
• Network with all the event attendees: Connect, see who’s attending, chat and share contact details with all online delegates, speakers and sponsors
• Exhibit a Virtual Booth: You can pack your customised booth full of documents, videos and even show who is manning the booth during the event and hosting meetings
• Host & Join Meetings & Socials: Join preferred speaking sessions, host you own meetings and even a virtual Networking social, with in built Zoom functionality

Vice President/ Heads of/General Managers:
• International Trade and Relations
• Supply Chain Development – Brexit
• Brexit Implementation
• Market Access
• Supply Chain Manager
• Parallel trade reporting
• Regulatory Affairs
• IP
• Purchasing
• Policy Patent Operations
• European Affairs
• Supply and Demand
• Attorney
• Distribution
 

AbbVie; AIFA - Agenzia Italiana Del Farmaco; Amgen Europe BV; Arnold & Porter; Baker & Mckenzie; bij CyTuVax b.v. ; Bristows LLC; Covington & Burling; Daiichi Sankyo Europe GmbH; Department of Health and Social Care; EAEPC; Erasmus University Rotterdam; Europe Economics; European Alliance for Access to Safe Medicines; European Association of Euro-Pharmaceutical Companies ; Ferring Pharmaceuticals; FERRING SA; Freshfields Bruckhaus Deringer LLP; Gilead Sciences Ltd; Hollister Europe Ltd; Intellectual Property Office; IQVIA; IQVIA Commercial GmbH & Co. OHG; Key Pharmaceuticals Ltd; Kopinke; LEO Pharma; Lisman Legal Life sciences B.V.; Medac GmbH; MHRA; MSD Animal Health ; Mundipharma; Novartis Pharma AG; Novartis Pharmaceuticals UK Ltd; Novo Nordisk Bioindustrie Sa; Novo Nordisk Ltd; SoftGroupáLtd.; UEA, University of East Anglia; White & Case LLP; Wiggin LLP; Windt Le Grand Leeuwenburgh;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Kasper Ernest

Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
View Bio

9:10 Managing Parallel Trade: An innovator’s perspective

Eric Noehrenberg

Eric Noehrenberg, President , NIPC

• Parallel trade makes medicines more “affordable”, but for whom?
• Impact of parallel trade
• Management of challenges posed by parallel trade
 

9:50 Exploring the impact of Brexit on Parallel Trade

Olga Ruppert

Olga Ruppert, Senior Legal Advisor, Affordable Medicines Europue
View Bio

• Examining the actions that parallel exporters to the EEA and intellectual property rights holders will need to take after the transition period
• How does Brexit affect the future of parallel trade?
• Examining how the EEA will treat products sold in the United Kingdom and exported to the EEA following Brexit

 

10:30 Morning Coffee

11:00 Panel: Understanding how COVID-19 will continue to affect Parallel Trade

• Exploring how we have dealt with a shortage and restriction of medical products
• Examining how the supply chain has dealt with this shortage of products
• What has the export ban and the blocked movement of products meant for parallel trade?
• How are manufacturers going to supply during this period?
• Future implications?
 

Vimal Unewal

Vimal Unewal, PT across Europe, Ferring Pharmaceuticals Ltd
View Bio

Richard  Freudenberg

Richard Freudenberg, President - Chief Executive, EAEPC
View Bio

Tine Petric

Tine Petric, Head Channel Management RE, Novartis Pharma AG

Olga Ruppert

Olga Ruppert, Senior Legal Advisor, Affordable Medicines Europue
View Bio

11:40 Understanding the exhaustion of IP rights

Christopher Stothers

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

• The traditional doctrine of EEA exhaustion
• Rebranding: Joined Cases C-253/20 and C-254/20 Impexeco / PI Pharma
• Exhaustion in Brexit Britain, now and in the future
 

12:20 Networking Lunch

13:20 Panel: Export bans and Parallel Trade

• Exploring how export bans are limiting sourcing opportunities of traders to understand how trade is decreasing
• Will these export bans be kept up in the future?
• Identifying the impact of COVID-19 on export bans in order to understand its significant effect on parallel trade
• What will happen with export bans once the COVID problems are solved?
 

Vimal Unewal

Vimal Unewal, PT across Europe, Ferring Pharmaceuticals Ltd
View Bio

Kasper Ernest

Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
View Bio

Fabrizio Gianfrate

Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara and Rome
View Bio

Soeren Brenoee

Soeren Brenoee, Senior Economist, Copenhagen Economics
View Bio

14:00 Analysing competition policies and Parallel trade

Sharon Malhi

Sharon Malhi, Antiturst, Competition and Trade, Freshfields Bruckhaus Deringer LLP
View Bio

• EU competition law and parallel trade: an overview
• Post-Brexit: understanding the key changes
• The future of competition policy and parallel trade: where from here?
 

14:40 Afternoon Tea

15:10 Case study: Pharma patent settlement

• IP strategy when considering a multijurisdictional patent settlement
• EU competition law implications and limitations in patent settlements
• Is it a battle between IP law vs competition law or do they seek achieve the same aims?
• Export bans/exhaustion/other restrictions/supply chains/Brexit and COVID
 

Beatriz San Martin

Beatriz San Martin, Partner, Arnold & Porter
View Bio

John Schmidt

John Schmidt, Partner, Arnold and Porter
View Bio

15:50 Status Quo on the German PI market – Effects of recent legislation changes (GSAV in 2019)

Robert Bayerl

Robert Bayerl, Engagement Manager, IQVIA Commercial GmbH & Co. OHG

• PI incentives in Europe's biggest market - short history overview and recent changes (GSAV)
• Effects on products recently excluded from legal incentives
• Future challenges for the German PI market
 

16:30 Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market

Farasat Bokhari

Farasat Bokhari, Senior Lecturer, Associate Professor, UEA, University of East Anglia
View Bio

• Do innovative firms increase product lines to deter entry, and if so, when is such a strategy successful?
• Using data from UK pharmaceuticals to examine how incumbents respond to change in the threat of entry
• Examining the originators’ product launch rate is higher when the risk of entry is moderate, but becomes lower when entry is very likely, and the effect is most pronounced in medium size markets
• Exploring that in medium size markets, originators can deny entry via proliferation if they fill the product space evenly across patients so that each variant has a significant market share of the originator’s drugs
• Understanding that this does not work in large markets, but here entry is deterred when originators engage in product hopping, i.e., shift most of the patients to newer variants of the drug that may still be protected by intellectual property
 

17:10 Chairman’s Closing Remarks and Close of Day One

Kasper Ernest

Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
View Bio

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Kasper Ernest

Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
View Bio

9:10 Pinpointing the key trends of Parallel Trade within Europe

Martin Slegl

Martin Slegl, Regional Principal of East Europe, IQVIA
View Bio

• Overview of Parallel Trade sales trends across the EU in 2020
• Exploring the key drivers of parallel trade across Europe
• Analysing the effect of Brexit and COVID-19 and their impact on supply chain
• What is the data based on?
• Differences between countries?
 

9:50 The advantages of parallel imports from the payer’s perspective

Soeren Brenoee

Soeren Brenoee, Senior Economist, Copenhagen Economics
View Bio

• What are the savings from parallel imports?
• How to quantify those savings?
• What regulation encourages and discourages parallel trade?
 

10:30 Morning Coffee

11:00 Examining how Parallel Trade can affect pricing across member states

Fabrizio Gianfrate

Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara and Rome
View Bio

• Insight into current pricing policies
• How can pricing policies help to eliminate Parallel trade?
• Exploring how pricing systems deal with parallel imports to understand if they stimulate Parallel Trade or create unfairness
• Has the price competition increased?
 

11:40 Falsified Medicines Directive: implications for parallel importers and of Brexit

Kasper Ernest

Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
View Bio

• Current research and findings from a global viewpoint to explore the effect on drug supply
• Examining how Parallel Traders can put more of a packaging and IT infrastructure in place to comply with the Falsified Medicines Directive
• Overview of the safety features including the Anti-Tamper Device and Unique Identifier to understand how these safety features work for Parallel Imports
• Exploring how many challenges have arisen from safety features including database issues and interpretations issues to understand whether such processes are efficient
• Examining how many packages have been identified as falsified in order to understand how successful the implementation of the FMD has been
 

12:20 Networking Lunch

13:20 Exploring cases associated with the Falsified Medicines Directive

Peter Bogaert

Peter Bogaert, Managing Partner, Covington & Burling
View Bio

• Examples of discussions points under the FMD
• What are we seeing in practice?
• What can we learn from these examples?
• Other experiences
• What countries are doing?
 

14:00 Regulatory issues relevant to parallel trade

Jackie Mulryne

Jackie Mulryne, Partner - Life Science Regulatory, Arnold & Porter
View Bio

• Overview of regulatory considerations, authorisations and licences
• Discussion of recent case law and current areas of dispute: including C-602/19, kohlpharma (changes to parallel import licences) and Case C-387/18, Delfarma (parallel trade of generic products)
• Outstanding questions, including C-147/20, Novartis (the impact of the Falsified Medicines Directive)
• Guidance from the EMA, including considerations where product is subject to special conditions for distribution
 

14:40 Afternoon Tea

15:10 Online platform for reporting of drug deficiencies - Bulgarian parallel-trade experience and results

Boryana Marinkova

Boryana Marinkova, CEO, BAMPTD - Bulgarian Association for Parallel Trade Development
View Bio

• Patient oriented project in collaboration with patients organizations and media coverage and follow-up
• Over 1200 patients signals served
• Innovation award in 2019
 

15:50 A view from the continent: Experience from Belgium

Tanguy Schmitz

Tanguy Schmitz, President, BAPIE (Belgian Association of Parallel Importers and Exporters asbl)

• Brexit and importation of medications in Belgium?
• Covid 19: the crisis and lessons taken
• Export ban legislation and answers from the Constitutional court
• FMD: How to digest the massive amount of false alert messages
 

16:30 Chairman’s Closing Remarks and Close of Day Two

Kasper Ernest

Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
View Bio

+

FEATURED SPEAKERS

Beatriz San Martin

Beatriz San Martin

Partner, Arnold & Porter
Boryana Marinkova

Boryana Marinkova

CEO, BAMPTD - Bulgarian Association for Parallel Trade Development
Eric Noehrenberg

Eric Noehrenberg

President , NIPC
Fabrizio Gianfrate

Fabrizio Gianfrate

Professor of Health Economics, University of Ferrara and Rome
Jackie Mulryne

Jackie Mulryne

Partner - Life Science Regulatory, Arnold & Porter
Kasper Ernest

Kasper Ernest

Secretary General, European Association of Euro-Pharmaceutical Companies
Martin Slegl

Martin Slegl

Regional Principal of East Europe, IQVIA
Olga Ruppert

Olga Ruppert

Senior Legal Advisor, Affordable Medicines Europue
Peter Bogaert

Peter Bogaert

Managing Partner, Covington & Burling
Richard  Freudenberg

Richard Freudenberg

President - Chief Executive, EAEPC
Sharon Malhi

Sharon Malhi

Antiturst, Competition and Trade, Freshfields Bruckhaus Deringer LLP
Soeren Brenoee

Soeren Brenoee

Senior Economist, Copenhagen Economics
Vimal Unewal

Vimal Unewal

PT across Europe, Ferring Pharmaceuticals Ltd

Beatriz San Martin

Partner, Arnold & Porter
Beatriz San Martin

Beatriz San Martin focuses her practice on the life sciences sector and innovative technologies. She has significant experience handling cases before the UK Courts and the Court of Justice of the European Union, including high-profile European litigation. In addition to her patent and SPC experience, she also counsels on and litigates other IP rights including copyright, trademark, passing off, design rights, database rights and confidential information. Her cases have involved a wide range of technologies including pharmaceuticals, medical devices, agrochemicals, insulation products, software, medical imaging and mosquito nets.

Boryana Marinkova

CEO, BAMPTD - Bulgarian Association for Parallel Trade Development
Boryana Marinkova

Boryana Marinkova is the CEO of the Bulgarian Association for Medicines Parallel Trade Development (BAMPTD). Marinkova is responsible for the implementation of the BAMPTD goals, which are to ensure the access of Bulgarian patients to quality and effective pharmaceutical products under competitive conditions and to initiate changes for rapid parallel import of medicines. She has 11 years of experience as a Marketing director at the international healthcare investment Tokuda Hospital since the opening of the largest private hospital in Bulgaria. She was there managing the implementation of the marketing plan, corporate communications and strategic development. In the period 2012-2017 she was responsible for the corporate affairs and the PR of the Bulgarian National Association of Private Hospitals. She has a Master degree in Marketing at the University of National and World Economy in 2004 after a Bachelor's program in Economics at UNWE. She is certificated by BEIED in Professional Marketing Management in 2009 and Professional Executive Management in 2015. Currently she is undergoing a PhD program in Public Administration and a lecturer in Integrated Marketing Communication at the University of National and World Economy.
 

Eric Noehrenberg

President , NIPC
Eric Noehrenberg

Fabrizio Gianfrate

Professor of Health Economics, University of Ferrara and Rome
Fabrizio Gianfrate

Fabrizio Gianfrate, 51, (Rome, Italy), degree and Master in Health Economics at University of Rome, specializations in Business Management at London School of Economics, Health Economics at Stockolm Economic School, Advanced Health Economics and Pharmacoeconomics at University of York, Economic Journalism at University of Verona. Actually Professor of Healthcare and Pharmaceutical Economics, Management, Mktg and Legislation at LUISS (University and Business School of Association of Italian Manufacturers – Confindustria) in Rome and Public University of Ferrara. Editor-in-Chief of Tecnica Ospedaliera and NCF, in the past director of Aboutpharma magazine (IMS Health Group). Consultant for pharmaceutical industries at national and international level and healthcare institutions in pricing & reimbursement, policies, Mkt access, HTA, public affairs, strategic mktg, communication. Registered journalist, columnist for healthcare and pharmaceuticals newspapers and magazines. Appointed in the past as Director at Ministry of Health, role then not executed, before he was General Manager and Vice President of Smith Kline Foundation Italy, after holding several management roles in pharmaceutical industry in business and strategies, with secondments in UK and US and as member of EFPIA groups.

Farasat Bokhari

Senior Lecturer, Associate Professor, UEA, University of East Anglia
Farasat Bokhari

Farasat Bokhari is an Associate Professor in the School of Economics and Centre for Competition Policy at the University of East Anglia. He is a health economist with a background in applied microeconomics and industrial organization, with a specialization in health policy. He has conducted research related to impact of public health financing on health outcomes as well as of other regulations on healthcare utilization. Dr. Bokhari’s research extends to competition and antitrust in the healthcare sector. His recent work is on welfare effects of new entrants, particularly of generic and follow-on (`me-too') drugs in the pharmaceutical markets. He has been active in studying firm strategies relating to pricing, launch of authorized generics, conducting pay-for-delay deals, and product differentiation and mergers and their impact on industry performance and structure.

Jackie Mulryne

Partner - Life Science Regulatory, Arnold & Porter
Jackie Mulryne

Jackie Mulryne advises clients in the life sciences and MedTech sectors, and has a broad practice providing regulatory compliance and public policy advice. She advises on UK and EU law, and has experience with a range of regulatory issues that arise throughout the product lifecycle. She regularly develops strategies to help bring innovative products to market, and has assisted a number of client in developing and implementing cross-border regulatory and compliance programmes.
Jackie also advises on contentious disputes in the sector, and has extensive experience in public and administrative law challenges to the decisions of regulatory bodies.

John Schmidt

Partner, Arnold and Porter
John Schmidt

John Schmidt leads the UK Competition team in London. He has over 25 years of experience dealing with competition authorities and courts in the UK and the EU and regularly advises on complex competition conduct issues, investigations, litigation, and merger cases. He is dual-qualified in the UK and Germany and has a particular focus on the life sciences.
Mr. Schmidt has extensive experience advising pharmaceutical and medical device companies on pricing matters, including a number of reverse payment patent settlement cases both at the EU and UK level. He secured a number of case closures without an infringement findings in a number of CMA’s pharma investigations and he has assisted a number of companies in unannounced investigations by competition authorities.
Mr. Schmidt has been consistently ranked as a leading lawyer by Chambers UK ("very knowledgeable, easy to work with and adept at explaining complicated issues."), Chambers Europe, and Chambers Global, as well as The Legal 500.

Kasper Ernest

Secretary General, European Association of Euro-Pharmaceutical Companies
Kasper Ernest

Kasper Ernest has worked for the last 9 years in European affairs advocacy in Brussels. From 2009 -2018 he was with the Confederation of Danish Enterprise, since 2015 serving as Director of the EU & International Department. He has also served as the Board Member of several EU-level business organisations, as a Member of the Danish Government’s Implementation Council, and was co-founder of the European Business Services Alliance. In addition, he is an external lecturer at Copenhagen Business School. He holds a Master’s degree in International Business and Politics from Copenhagen Business School and Singapore Management University.

Martin Slegl

Regional Principal of East Europe, IQVIA
Martin Slegl

Martin has over 9 years experience in the area of management consulting, he was leading South East Europe consulting with IQVIA (10 countries). His current role is General Manager for the Czech Republic and Slovakia. His specialty is cross border trade and he has worked for a large number of HQs across Europe in different therapy areas. He has proven project experience across a variety of industries through Europe as he worked with Roland Berger and A.T. Kearney. Martin holds CEMS Master's in International Management and Master’s in Business Economics degrees from ESADE and University of Economics in Prague.

Olga Ruppert

Senior Legal Advisor, Affordable Medicines Europue
Olga Ruppert

Olga Ruppert is a German qualified lawyer with extensive experience in health and medicines law, policy making and complex litigation. In addition to her legal degree she holds a Master in Interdisciplinary European Studies from the College of Europe. Before joining Affordable Medicines Europe, Olga worked for the Federal Union of German Associations of Pharmacists in Berlin and international law firms in Brussels.

Peter Bogaert

Managing Partner, Covington & Burling
Peter Bogaert

Peter Bogaert is a managing partner of the Brussels office, and has a broad European life sciences practice. He has detailed regulatory expertise under EU and national laws, handles legislative and other policy assignments and provides strategic advice. He also represents life sciences companies before the European Courts in Luxembourg and in local litigation in Belgium. Mr. Bogaert's practice covers pharmaceuticals, biotechnology, medical devices, special foods and feed, cosmetics and other consumer products and he represents numerous innovative life sciences companies, including start-ups, as well as several industry associations.
Chambers Global notes that a client said “He is an extremely experienced professional with broad expertise and provides sensible and well-balanced solutions." He is consistently ranked by PLC as one of the leading life sciences lawyers globally and Legal 500 EMEA and Chambers Europe note Mr. Bogaert's prominent regulatory pharmaceutical and environmental practice. Legal 500 EMEA (2011) noted that he is "a superb lawyer who is very pleasant to work with." Mr. Bogaert regularly writes and speaks on life sciences issues. He is a founding member of the Brussels Pharma Law Group.

Peter Bogaert

Managing Partner, Covington & Burling
Peter Bogaert

Richard Freudenberg

President - Chief Executive, EAEPC
Richard  Freudenberg

Richard Freudenberg has worked in the PPDI since 1990, for 15 years as Finance Director and subsequently as Managing Director of founder BAEPD member, Doncaster Pharmaceuticals Group Limited.
Richard has also been a BAEPD Director and member of the association's managing Council from December 2001, and acceded to the BAEPD secretariat in 2005. He has during this period also been (since 2011) Chief Executive of, and twice President (2007-2008 & 2011 to date) of EAEPC

Richard Freudenberg

President - Chief Executive, EAEPC
Richard  Freudenberg

Robert Bayerl

Engagement Manager, IQVIA Commercial GmbH & Co. OHG
Robert Bayerl

Sharon Malhi

Antiturst, Competition and Trade, Freshfields Bruckhaus Deringer LLP
Sharon Malhi

Recognised as one of 50 Future Female Leaders by the Financial Times, Sharon is a specialist EU and UK competition lawyer based in London. Having also spent time working in Brussels, she has experience of working on all aspects of EU and UK competition law including behavioural antitrust investigations, competition litigation, sector-wide market inquiries and global M&A.
As a leading member of the firm’s TMT and Digital practice, Sharon has particular experience in advising global technology, digital platform, healthcare and financial services infrastructure clients on contentious and non-contentious matters before the European Commission, the UK Competition and Markets Authority and the English High Court: particularly matters with a focus on data, innovation and/or the intersection of competition law with intellectual property law.

Soeren Brenoee

Senior Economist, Copenhagen Economics
Soeren Brenoee

Søren is an economics advisor within the field of healthcare and life sciences. He is the author of The economic impact of parallel imports of pharmaceuticals, a Danish study from 2019. His expe-rience ranges from design of value-based healthcare and risk-sharing models, impact evaluation, value demonstration of products and activities as well as strategic advice in relation to regulation. Søren is part of Copenhagen Economics, which is one of the leading economics firms in Europe, operating from offices in Copenhagen, Stockholm, Helsinki, and Brussels.

Tine Petric

Head Channel Management RE, Novartis Pharma AG
Tine Petric

Vimal Unewal

PT across Europe, Ferring Pharmaceuticals Ltd
Vimal Unewal

Vimal Unewal is currently the Head of In-Market Supply for Ferring Pharmaceuticals, looking after the Parallel Trade across Europe. Vimal has 25 years of experience in supply chain and commercial across EMEA, Asian, Latin and North American markets for branded and generics pharmaceuticals, FMCG, and automotive. Vimal holds a B.Sc. in Business Management from University of Lisbon and a frequent speaker at supply chain conferences. Vimal lives in Berkshire (UK) and he’s interested in music and table tennis.

Exhibitors

Workshops

The law of parallel trade: past, present and future
Workshop

The law of parallel trade: past, present and future

Online Virtual Event
24th March 2021
Online Virtual Event , United Kingdom

VENUE

Online Virtual Event

Online Virtual Event , Online Virtual Event , United Kingdom

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

Chair Letter 2021

Download

Speaker Interview with Dr Eric Noehrenberg, President, NIPC

Download

Parallel Trade Speakers bios 2021

Download

Parallel Trade Short Programme 2021

Download

Parallel Trade Full Programme 2021

Download

Past Attendees List

Download

PAST PRESENTATION BY Peter Bogaert & Wesley Lepla, Covington

Download

PAST PRESENTATION BY Jeremy Blum, Bristows LLP

Download

PAST PRESENTATION BY Dermott Glynn, Europe Economics

Download

PAST PRESENTATION BY Beatriz San Martin, Arnold & Porter

Download

Exhibitors


UL Global Pharma

Exhibitors
http://www.ul-globalpharma.com

Founded in 2019, UL Global Pharma Limited is a pharmaceutical wholesaler which sources and supplies primarily specialist hospital products including imported unlicensed medicines and alternative products to UK Shortage lines.

A specialised team who are experts in globally sourced unlicensed medicines, with stock lines available for next-day delivery to anywhere in the UK.

Close working relationship with DHSC and MHRA mean we can prepare and stock products for shortages before they are critical. In market procurement across the UK, US and Germany due to licensed facilities enables us to source from a global network.

In August 2019, Orifarm based in Odense, Denmark wholly acquired UL Global Pharma Ltd and part of a global group of companies procuring more than 4,000 unique products and speciality, from 26 purchase markets and 4 production facilities. This rigorous supply means we can offer Parallel Imports and branded generic therapies ensuring competitive pricing and saving for all markets.


SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Online Virtual Event

Online Virtual Event
United Kingdom

Online Virtual Event

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out